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Amyotrophic lateral sclerosis (ALS) is a progressive, uniformly fatal, degenerative
disorder of the upper motor neurons that does not currently have an effective treatment
regimen. Here, we report two patients with ALS who were treated with 4 weeks of
acupuncture injection point therapy using Enercel. These patients were administered
0.25e0.5 cc Enercel Plus IM to specific acupuncture points for 5 days per week for 4
weeks. Patient #1 presented with flaccid paralysis of all four extremities and impaired
speech and swallowing. By Week 4, she demonstrated significant improvement in her
motor strength in all four extremities (R> L) and improved speech and swallowing.
However, she did not continue to receive the Enercel acupoint injections, and she subse-
quently demonstrated a slow, progressive loss of neurological function during the ensuing
3 months, as shown on follow-up examinations. Patient #2 had significantly impaired
speech and mild motor loss in the upper extremities and the left leg. After 4 weeks of
treatment, his voice had significantly improved to the point where his speech was under-
standable and his motor functions had returned to normal. He continued receiving Ener-
cel acupoint injections during the 3-month follow-up period and his clinical improvements
were maintained. Thus, these two patients with ALS showed clinical improvements after
4 weeks of Enercel acupoint injection therapy. Follow-up data suggests that ongoing
therapy may be necessary in order to maintain these positive effects. This preliminary
study merits further study and confirmation.1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal
neurodegenerative disease that is characterized by the lossh Advanced Technologies, 2477 S
uncture Instituteof motor neurons (i.e., the nerve cells that control volun-
tary muscle movement) [1]. The disorder causes muscle
weakness and muscle wasting throughout the body as both
the upper and lower motor neurons degenerate.tickney Point Dr., Suite 200A, Sarasota, FL 34231, USA.
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worldwide. One or two out of every 100,000 people
develop ALS each year. ALS most commonly strikes people
between 40 and 60 years of age, but younger and older
people can also develop the disease. Men are affected
slightly more often than women [2]. The cause of ALS is
unknown [3].
ALS usually advances to progressively more severe motor
neuron disease, and eventually death, within 2e5 years.
The pharmaceutical drug Rilutek has been shown to prolong
survival for up to several months and may slow the time
required to reach respiratory failure [4]. However, no
available medication can reverse motor neuron degenera-
tion or provide a cure.
Enercel (World Health Advanced Technologies, Nassau,
Bahamas) is a combination of various homeopathic medi-
cines, as defined by the Homeopathic Pharmacopoeia of the
United States (HPUS). The ingredients include Cactus
Grandiflorus (4X), Aloe Socotrina (4X), Abies Nigra (4X),
Arnica (6X), Lachesis (11X), calcium carbonate (6X), Pul-
satilla Vulgaris (6X), distilled water, and alcohol (5e8% by
volume). Enercel has been shown to be completely
nontoxic and has not demonstrated any negative side
effects in clinical trials or general use [5]. Enercel supports
immune system functions by stimulating energy production
in the cells and modulating their activity. Anecdotal reports
have reported that Enercel is beneficial for patients with
neurodegenerative disorders, although it has never been
formally studied in this population.
Enercel activates the energy pathways of tissues
throughout the body [6]. This energy enhancement results
in improved functioning, health, metabolism, and resis-
tance to infection and stress. Once the cellular energy is
normalized, particularly in the immune system, health can
be restored and patients are able to carry on their normal
activities. Furthermore, because all of the tissues in
a localized area are affected in the same way, homeostasis
between cells is restored as well. When cells have sufficient
and regulated energy, their functions are normalized [7].
Acupuncture is a technique used in traditional Chinese
medicine, whereby a number of very fine metal needles are
inserted into the skin at specially designated points [8]. The
conventional Chinese explanation of the effectiveness of
acupuncture is based on the Taoist philosophy that explains
that good health depends on the free circulation of chi (qi),
or life force energy, through all of the organs of the body.
The chi, in turn, depends upon the balance of the two
opposing energies: yin (negative, dark, feminine) and yang
(positive, bright, masculine). Meridians are the main chan-
nels of this flowing energy. When energy flow is impeded at
any point (e.g., because of a diseased organ or stress),
illness in other organs may result. Piercing the channels at
the proper points is believed to correct imbalances by
modulating energy flow.
Energy medicine is based upon the belief that changes
in the “life force” of the bodydincluding the electric,
magnetic, and electromagnetic fieldsdcan affect human
health and be manipulated to promote healing. Alterna-
tively, a new concept in energy medicine incorporates the
network of underdifferentiated, electromagnetically sensi-
tive cells in the body that can be “triggered” by energetic
substances to induce tissue repair and regeneration [8].The notion of the life force or energy is shared by people
around the world. Since ancient times, traditional cultures
have believed that a special energy vitalizes all life. This
energy is known by many other names. It is intriguing to
consider that this ancient concept of bio-energy may now
be in the process of being defined by science by stem cell-
like, electromagnetically sensitive cells in the body that are
capable of cellular reconstruction and restoration.
Over the course of the last three decades, energy
medicine has moved from being a marginal area of research
to gaining a considerable amount of mainstream accep-
tance. Despite the publication of over 300 studies over the
past 40 years that report the efficacy of energy healing,
these findings are still ignored or rejected by many scien-
tists due to nonreproducible or inconsistent results [9].
The injection of liquids into acupuncture pointsdeither
pharmaceutical or naturaldis called acupuncture injection
point therapy. This treatment is based on the concept that
products that enhance energy channels may work syner-
gistically with acupuncture. Animal trials have validated
this process in several models, including acupoint injections
of bee venom to treat adjuvant-induced arthritis [10].
Although few clinical trials are available, extensive
community experiencedespecially in Chinadhas yielded
results beyond what may be achievable by acupuncture or
drug supplementation alone. This practice is a recognized
procedure in several states, including Florida, Arkansas,
Colorado, New Mexico, and Washington.
The administration of Enercel into acupuncture points
has been named enerpuncture. This procedure has proved
to be beneficial for treating patients with a variety of
illnesses, most commonly those affecting the musculo-
skeletal system [11]. Clinical experience suggests that
acupoint injection with Enercel may improve the clinical
outcomes of many disorders compared to acupuncture
alone. This report describes neurological improvement in
two patients with ALS who received 4 weeks of ener-
puncture therapy.
2. Presentation of cases
2.1. Case #1
A 59-year-old Caucasian female presented with a medical
history of osteoarthritis, hypertension, and depression, all
of which were well controlled. She presented with a 1-year
history of progressive weakness in all four extremities,
fasciculations, poor gait, and 5 months of wheelchair
dependence. These symptoms first began to present about
1 year prior when she noted difficulty getting in and out of
her SUV and difficulty rising from a seated position. She
initially attributed these symptoms to osteoarthritis, but
she began to have progressive problems with mobility and
experienced frequent falls. These problems advanced to
the point that she completely lost movement in all four of
her extremities. She had an initial clinical examination in
December 2009 that revealed spinal stenosis; she under-
went a laminectomy on January 19, 2010 to treat this.
Despite the surgery and subsequent rehabilitation, her
neurological condition continued to worsen. She was re-
admitted in March 2010 for a physical examination that
Table 1 Initial acupuncture points used in this study.
Acupuncture Point Enercel dose* Durationy
Baihui Du-20 none 4 wk
Huatuojiaji EX-21 0.25 cc 4 wk
Dazhui DU-14 0.25 cc 4 wk
Quchi LI-11 0.25 cc 4 wk
Waiguan SJ-5 0.25 cc 4 wk
Yanglingquan GB-34 0.25 cc 4 wk
Zusanli ST-36 0.25 cc 4 wk
Dicang ST-4 0.25 cc 4 wk
Jianche ST-6 0.25 cc 4 wk
Liangmen ST-21 0.25 cc 4 wk
Tianshu ST-25 0.25 cc 4 wk
Guilai ST-29 0.25 cc 4 wk
Genshu UB-17 0.25 cc 4 wk
Qimen LIV-14 0.25 cc 4 wk
Pishu UB-20 0.25 cc 4 wk
Weishu UB-21 0.25 cc 4 wk
Hagu LI-4 0.25 cc 4 wk
Jianyu LI-15 0.25 cc 4 wk
Yanglao SI-6 0.25 cc 4 wk
Huantiao GB-30 0.25 cc 4 wk
Shangjuxu ST-37 0.25 cc 4 wk
Jiexi ST-41 0.25 cc 4 wk
Kunlun UB-60 0.25 cc 4 wk
* Injects were delivered to each acupuncture points using a 27-
gauge needle. The dose could be raised to 0.5 cc during the
study at the acupuncturist’s discretion.
y Patients were treated Monday through Friday with the
weekends off. The acupuncturist was free to add or subtract
new points during the course of the 4-week treatment period
based on his clinical evaluation at each visit.
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extremities, diffuse hyperreflexia, and a bilateral positive
Babinski’s reflexes. Laboratory values were as follows
[normal values are shown in brackets]: normal blood
chemistry panel; negative for antibodies to human immu-
nodeficiency virus (HIV) 1-2; erythrocyte sedimentation
rate (ESR), 32 mm/hr [0e20 mm/hr]; C-reactive protein
(CRP), 2.34 mg/dL [0e1 mg/dL]; copper level, 219 mg/dL
[80e155 mg/dL]; white blood cell count (WBC), 10.09 k/mL
[4.5e11 k/mL]; red blood cell count (RBC), 3.70 m/mL
[4.2e5.5 m/mL]; hematocrit (HCT), 34.4% [37e47%];
platelet count, 419 k/mL [150e400 k/mL]; vitamin B12,
376 pg/mL [200e900 pg/me]; thyroid stimulating hormone
(TSH), 2.16 mIU/mL [0.55e4.78 mIU/mL]; T4, 0.8 ng/dL
[0.8e1.8 ng/dL]; methylmalonic acid, <0.10 mmol/L
[0e0.4 mmol/L]; Urinalysis (UA) within normal limits (WNL);
urinary lead and arsenic, < 0.10 mg/L [<0.10 mg/L]; urinary
mercury, 3 mg/dL [0e10 mg/dL]; cerebrospinal fluid (CSF)
protein, 35 mg/dL [10e50 mg/dL]; glucose, 57 mg/dL
[40e70 mg/dL]; WBC, 3 per cmm [0e5 per cmm], RBC, 233
per cmm [0e1 per cmm]; nonreactive Venereal Disease
Research Laboratory (VDRL); negative cytology; negative
gram staining; slightly elevated IgG synthesis, 4.39 mg/day
[-9.9-þ3.3 mg/day].
Imaging studies were also performed. MRI of the cervical
spine showed mild degenerative changes; however, brain
MRI, pelvic MRI, and CT of the abdomen were all negative.
Abdominal ultrasound was unremarkable and pelvic sono-
gram was normal except for a 3 cm cyst in the left ovary.
Pulmonary function tests revealed mild restrictive lung
disease. Doppler studies of the lower extremities were WNL.
Electromyogram/Nerve conduction velocity (EMG/NCV) tests
showed patchy denervation in both legs and arms with
fasciculations in the proximal right arm and left leg muscles.
The tongue was normal. The thoracic paraspinous muscles
were not studied. Conduction studies indicated that the legs
were nonconductible due to distal atrophy and denervation.
Proximal right peroneal NCVwas normal and the rightmedian
was also normal. A diagnosis of amyotrophic lateral sclerosis
was made based on these findings.
Patient #1 presented on July 12, 2010 with flaccid
paralysis of all four extremities (some fasciculations were
noted but strength was 0/5 in all extremities). Her speech
was impaired and her swallowing was minimally impaired.
The neck paraspinal muscles were in spasm and their
strength was 3/5. Her hands and fingers had severe
contractures. She had 3þ pitting edema in both legs
through the knees and 1þ in both arms (L> R). Her
prescribed medications included the following: 50/25 mg
qd Atenolol/HCTZ; 100 mg bid Colace; 20 mg bid Lasix; 10
meq bid potassium chloride; 300 mg tid Gabapentin; 2 mg
qd Estradiol; 0.5 mg bid/prn Lorazepam; 20 mg Omepra-
zole; 20 mg bid Oxycodone; 25 mg qd Sertraline; and 50 mg
bid Rilutek. All of her medications were continued
throughout the course of this study.
Patient #1 began acupuncture injection point treat-
ments with 0.25e0.5 cc of Enercel Plus IM that was
administered to each point for 5 days per week, as specified
in the protocol (Table 1). The practitioner was free to vary
and/or add acupuncture points as the study progressed. She
also received intramuscular injections of 3 cc Enercel Plus
IM 5 days per week, 20 drops of Enercel Max administeredsublingually twice daily, and 10 drops of Enercel Max in 16
oz of water twice daily.
Approximately 4 days into the study, she developed some
grip in both hands (R> L) and 2/5 movement in her right
arm. Her speech and neck strength improved. A day later
she developed a “detoxification reaction,” which is char-
acterized by severe fatigue, muscles aches, light headed-
ness, increased edema, and complaints of feeling feverish
(although her body temperature remained normal). Her
Enercel-containing water was withheld because of the
increased edema. Her urine became cloudy, which is
consistent with the detoxification process, but the dipstick
analysis was negative for leukocytes. She was started on
a detoxification regimen of Zeolite drops (Metagenics, Gig
Harbor, Washington) (10 drops administered sublingually
three times per day) and AdvaClear (Metagenics, Gig
Harbor, Washington) (two capsules administered three
times per day).
She continued to have detoxification reactions, but
another neurological examination performed 4 days later
(Day 8) revealed increased movement in her right arm and
some movement in her left arm. Her grip strength had
improved bilaterally. She could now wiggle her toes some.
Up to this point, her nutritional status was poor. She was
started on protein shakes supplemented with powdered
greens mixture twice per day, but her oral intake was still
poor. She was also severely constipated, which was resolved
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intermittent use of oral magnesium sulfate (Epsom salts).
The detoxification symptoms became so severe and
constant that her acupoint injections were decreased,
primarily by withholding the injections to her legs. Despite
that, by Day 12, she continued to show improvements in
speech, arm and hand strength, and toe and foot movement
compared with her condition on Day 8. Her neck strength
had improved to 4/5 and the spasms were resolved.
Laboratory tests were performed after 14 days,
revealing a potassium level of 2.0 mEq/L. This is thought to
be secondary to the two potassium-voiding diuretics that
were prescribed (Lasix and HCTZ). HCTZ was discontinued
and the patient was briefly hospitalized for intravenous
potassium replacement. After obtaining a potassium level
of 3.7 mEq/L, she was released.
The detoxification reactions decreased and she restar-
ted full acupoint treatments. After 3 weeks on this study,
her neurological improvements were as follows: speech had
improved by 50%; right grip strength was 4þ/5; lower arm
strength was 3þ/5; upper arm strength was 3/5 (she was
somewhat able to grip and manipulate her wheelchair
controls); left grip strength was 3/5; lower arm strength
was 3/5; upper arm strength was 2/5; she was able to
wiggle the toes of both feet; raised foot and lower leg
movements were both rated as 3/5; some movement of the
proximal muscles was noted (2/5); and neck extensors and
flexors were now rated as 5/5.
After about 3 weeks, her appetite began to improve and
she was able to eat three full meals per day up to the end of
the initial 4-week study period. Her ability to swallow had
significantly improved.
At the end of the initial 4-week study period, her muscle
strength was similar to that measured at 3 weeks, but her
coordination in her right hand had improved enough that
she was able to easily manipulate the controls of her
wheelchair for mobility and positioning. Her speech had
also improved. She was now able to push up on her elbows,
buttocks, and thighs in order to assist during transfers.
The patient returned home where she was followed via
telephone conversations for 3 months. No follow-up testing
was performed by her private physiciansdshe was only
evaluated using clinical and neurological examinations.
State restrictions on acupuncture injection point therapy
prevented her from continuing this therapy; instead, she
was treated 2e3 times per week with standard acupunc-
ture. She intermittently used intramuscular, oral, and
sublingual Enercel. Her clinical status slowly worsened over
the following 3 months, although at the end of the follow-
up period her condition was still improved compared with
baseline (Table 1).2.2. Case #2
A 49-yeareold, Caucasian, male, Gulf War without
a significant past medical history who reported a 16-month
history of progressive dysphagia and dysarthria and an 8-
month history of worsening bilateral upper arm twitching
and clumsiness of gait and grip. His daily activities were
minimally impacted, although it was difficult for him to
verbally communicate.The patient occasionally have trouble holding objects and
sometimes lost his balance, although he did not suffer any
falls. He had an extensive clinical examinations in March
2010 that revealed the following findings [normal laboratory
values are included in brackets]: slurred, nasal speech that
was moderately intelligible; tongue fasciculations; slightly
decreased motor strength left upper extremity (LUE);
fasciculation of both shoulders and upper extremities (UE);
chemistry panel, WNL; TSH, 1.40 mIU/mL [0.55e4.78 mIU/
mL]; free T4, 0.84 ng/dL [0.8e1.8 ng/dL]; prostate specific
antigen (PSA), 1.16 ng/mL [0e4 ng/dL]; WBC, 4.4 k/mL
[4.5e11 k/mL]; RBC, 4.84 m/mL [4.2e5.5 m/mL]; HCT, 42.7%
[37e47%]; platelet count, 194 k/mL [150e400 k/mL]; vitamin
B12, 247 pg/mL [200e900 pg/mL]; ESR, 9 mm/hr [0e20 mm/
hr]; serum protein electrophoresis (SPEP), WNL; CRP,
0.553 mg/dl [0e1 mg/dL]; total cholesterol, 187 mg/dL
[120e200 mg/dL]; UA, WNL; rapid plasma reagin (RPR) (-).
EMG/NCV showedwidespreadmotor neuron disease affecting
the tongue and bilateral upper limbs but sparing the thoracic
paraspinal muscles. Patchy denervation of both of the lower
extremities was evident, but no evidence of peripheral
neuropathy or significant neuromuscular transmission defects
were noted. Pulmonary function tests (PFT) showed mild
restrictive disease. MRI of the lumbar region was normal. Mild
spondylosis was noted on cervical magnetic resonance
imaging (MRI). The diagnosis of amyotrophic lateral sclerosis
was made based on these findings.
When patient #2 began treatment on July 19, 2010 his
clinical status was as follows: severe dysarthria to the point
of being only very minimally intelligible; tongue, bilateral
shoulder, and upper arm fasciculations; mildly decreased
LUE motor strength and left-hand grip; mildly decreased
left leg strength; mildly decreased right deltoid, brachior-
adialis, hand grip, and tibialis anterior strength; mildly
impaired toe-to-heel gait and left-leg clumsiness. Reflexes
were all normal. His medications included the following:
10 mg qd Loratadine; 20 mg qd Omeprazole; and 50 mg bid
Rilutek. All medications were continued through the course
of this study.
He began acupuncture injection point treatments with
0.25e0.5 cc Enercel Plus IM at each point for 5 days per
week, as specified in the protocol (Table 1). The practi-
tioner was free to vary and/or add points as the study
progressed. He also received 3 cc Enercel Plus IM adminis-
tered intramuscularly 5 days per week. He received 20
drops of Enercel Max sublingually and 10 drops of Enercel
Max in 16 oz of water twice daily.
After 1 week, his speech was somewhat improved and
more intelligible. His fasciculations were decreased and his
motor strength was 5/5 throughout his extremities, except
the LUE which were 4þ/5. His toe-to-heel gait had
improved slightly. He reported being able to handle objects
in both hands better. AdvaClear (two capsules) and Zeolite
(10 drops sublingually) were administered three times per
day to avoid any potential detoxification reactions.
After 2 weeks his speech was clearer and all motor
functions were normal. He developed some fasciculations
in his chest muscles, and the decision was made to add
chest muscle and diaphragmatic acupoint injections. His
toe-to-heel gait was normal. He reported the motor control
in his hands to be 80% improved from baseline. He felt well
and did not complain of any detoxification symptoms.
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and his clinical and neurological status were unchanged
from that reported in Week 2. He reported increased
energy and sense of well-being. His voice continued to
improve to the point where his speech was completely
understandable, though still moderately impaired. Fine
motor control in both hands, as reported by the patient,
was still 80% improved over baseline.
After 4 weeks, the chest fasciculations had improved by
>50% and his neurological motor status continued to
improve, except that the reported fine motor control of his
hands remained at 80% over baseline. His voice and speech
were slightly more improved. He reported a moderate
return of fasciculations in both arms after vigorous exercise
(jet skiing). The fasciculations were completely resolved by
the next morning.
The patient returned home, where he was followed via
telephone conversations for 3 months. No follow-up testing
was performed by his private physiciansdhe was only
evaluated by clinical and by neurological examinations. He
continued to receive the Enercel acupoint injections 3e5
times per week; the intramuscular, oral, and sublingual
Enercel were administered on the same schedule as during
the 4-week lead-in period. His clinical status remained
unchanged over the following 3 months. The positive
effects achieved during the initial 4 weeks of treatment
were maintained.
3. Discussion
Two patients with ALS were treated with 4 weeks of
acupuncture injection therapy using Enercel. These indi-
viduals demonstrated significant improvements in speech
and muscle strength in the extremities after treatment. The
patients were regularly contacted for 3 months after
receiving treatment. Patient #1 did not maintain the Ener-
cel acupoint injection treatments due to restrictions in her
home state. She did not receive regular Enercel adminis-
trations via oral, sublingual, or intramuscular routes. She
demonstrated a slow decline in neurological functioning
over the following 3 months, although at the end she hercondition was still better than that recorded at baseline.
Patient #2 continued regular Enercel acupoint injection
therapy and Enercel use. The clinical improvements he
achieved during the 4 weeks of intensive treatment were
maintained during the 3-month follow-up period. It appears
that persistent acupoint injection therapy with Enercel may
be required in order to maintain the initial positive effects.
However, these findings are preliminary. Additional, formal
studies and controlled clinical trials are required to expand
and confirm these results.
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